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1. Introduction
Calcific Aortic Stenosis is the most common cause of aortic valve disease in developed coun‐
tries. This condition increases in prevalence with the advancing age of the U.S. population,
afflicting 2-3 % by age 65 [1]. Aortic valve replacement is the number one indication for sur‐
gical valve replacement in the United States and in Europe. The natural history of severe
symptomatic aortic stenosis is associated with 50% mortality within 5 years [2]. Bicuspid
aortic valve disease is the most common congenital heart abnormality and it is the most
common phenotype of calcific aortic stenosis. The bicuspid aortic valve (BAV) is the most
common congenital cardiac anomaly, having a prevalence of 0.9 to 1.37% in the general pop‐
ulation [3]. Understanding the cellular mechanisms of tricuspid versus bicuspid aortic valve
lesions will provide further understanding the mechanisms of this disease. Currently, there
are three fundamental mechanisms defined in the development of aortic valve disease: 1)
oxidative stress via traditional cardiovascular risk factors [4-8,6, 7, 9-12], 2) cellular prolifera‐
tion [13] and 3) osteoblastogenesis in the end stage disease process [14, 15]. Previously, the
Wnt/Lrp5 signaling pathway has been identified as a signaling mechanism for cardiovascu‐
lar calcification [5, 16, 17]. The corollaries necessary to define a tissue stem cell niche: 1)
physical architecture of the endothelial cells signaling to the adjacent subendothelial cells:
the valve interstitial cell along the valve fibrosa. 2) defining the oxidative-mechanical stress
gradient necessary to activate Wnt3a/Lrp5 in this tissue stem niche to induce disease. Re‐
cently, the mechanisms of oxidative stress have been identified in the development of calcif‐
ic aortic valve disease. This chapter will outline the factors important in the role of calcific
aortic valve disease.
© 2013 Rajamannan; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. The role of lipids in vascular and valvular disease
The role of lipids in vascular atherosclerosis has been defined in the literature for years.
Atherosclerosis is a complex multifactorial process which produces a lesion composed of
lipids  [18,  19],  macrophages  [20],  and  proliferating  smooth  muscle  cells  [21]  apoptosis
[22] and extracellular bone matrix production [23] in the vascular wall [24, 25]. The acti‐
vation of  these  cellular  processes  is  regulated by a  number  of  pathways.  Integrins  pro‐
vide  an  important  role  in  the  regulation  of  cellular  adhesion  in  atherosclerosis  [26].
Another  critical  regulator  of  vascular  endothelial  biology  is  nitric  oxide  (NO)  [27,  28].
Cholesterol-rich LDL also has a  critical  role  in  the onset  and further  progression of  the
atherosclerotic lesion via an inactivation of endothelial  nitric oxide synthase (eNOS) [22,
29-31] contributing to an abnormal oxidation state within the vessel.  In this inflammato‐
ry environment, growth factors and cytokines are secreted to induce vascular smooth cell
proliferation and recruitment of macrophage cells [32-37] which are important in the de‐
velopment of the atherosclerotic plaque lesion.
Recently, similar risk factors for calcific aortic valve disease have recently been described in‐
cluding male gender, hypertension, elevated levels of LDL, and smoking [38, 39] which
mimic those that promote the development of vascular atherosclerosis. Surgical pathological
studies have demonstrated the presence of LDL and atherosclerosis in calcified valves, dem‐
onstrating similarities between the genesis of valvular and vascular disease and suggesting
a common cellular mechanism [40, 41]. Patients who have the diagnosis of familial hyper‐
cholesterolemia develop aggressive peripheral vascular disease, coronary artery disease, as
well as aortic valve lesions which calcify with age [10, 42]. Rajamannan et al, have shown
that the development of atherosclerosis occurs in the aortic valve in a patient with Familial
Hypercholesterolemia with the Low density lipoprotein receptor mutation [10]. The athero‐
sclerosis develops along the aortic surface of the aortic valve and in the lumen of the left cir‐
cumflex artery [10]. This provides the first index case of atherosclerotic aortic valve disease
in this patient population. Studies have confirmed in experimental hypercholesterolemia
that both atherosclerosis and osteoblast markers are present in the aortic valves [4, 6, 13].
This background provides the foundation for studying valve calcification in an experimental
atherosclerotic in vivo model.
3. Aortic valve calcification
The presence of calcification in the aortic valve is responsible for valve stenosis. Severe aort‐
ic stenosis can result in symptomatic chest pain, as well as syncope and congestive heart fail‐
ure in patients with severe aortic valve stenosis. For years, aortic valve stenosis was thought
to be a degenerative process. However, the pathologic lesion of calcified aortic valves dem‐
onstrate indicate the presence of complex calcification in these tissues. Furthermore, there
are a growing number of descriptive studies delineating the presence of bone formation in
the aortic valve [15, 43, 44].
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Until recently the etiology of valvular heart disease has been thought to be a degenerative
process related to the passive accumulation of calcium binding to the surface of the valve
leaflet. Recent descriptive studies have demonstrated the critical features of aortic valve cal‐
cification, including osteoblast expression, cell proliferation and atherosclerosis [6, 14, 15, 45]
and mitral valve degeneration, glycosaminglycan accumulation, proteoglycan expression,
and abnormal collagen expression [46-49]. These studies define the biochemical and histo‐
logical characterization of these valve lesions. We and others, have also shown that specific
bone cell phenotypes are present in calcifying valve specimens in human specimens [16, 50].
These data provide the evidence that the aortic valve calcification follows the spectrum of
bone formation in calcifying tissues.
4. The role of Lrp5/beta-catenin activation in cardiovascular calcification
and osteoblast bone formation: Connection with the bone axis
Bone and cartilage are major tissues in the vertebrate skeletal system, which is primarily
composed of three cell types: osteoblasts, chrondrocytes, and osteoclasts. In the developing
embryo, osteoblast and chrondrocytes, both differentiate from common mesenchymal pro‐
genitors in situ, where as osteoclasts are of hematopoietic origin and brought in later by in‐
vading blood vessels. Osteoblast differentiation and maturation lead to bone formation
controlled by two distinct mechanisms: intramembranous and endochondral ossification,
both starting from mesenchymal condensations.
To date only two osteoblast-specific transcripts have been identified: 1) Cbfa1 and 2) osteo‐
calcin (OC). The transcription factor Cbfa1 [51] has all the attributes of a ‘master gene’ differ‐
entiation factor for the osteoblast lineage and bone matrix gene expression. During
embryonic development, Cbfa1 expression precedes osteoblast differentiation and is restrict‐
ed to mesenchymal cells destined to become osteoblast. In addition to its critical role in os‐
teoblast commitment and differentiation, Cbfa1 appears to control osteoblast activity, i.e.,
the rate of bone formation by differentiated osteoblasts [51]. We have shown previously that
cholesterol upregulates Cbfa1 gene expression in the aortic valve and atorvastatin decreases
the gene expression [6] in an animal model. We have also demonstrated that Sox9 and Cbfa1
are expressed in human degenerative valves removed at the time of surgical valve replace‐
ment [16]. The regulatory mechanism of osteoblast differentiation from osteoblast progeni‐
tor cells into terminally differentiated cells is via a well orchestrated and well studied
pathway which involves initial cellular proliferation events and then synthesis of bone ma‐
trix proteins, which requires the actions of specific paracrine/hormonal factors and the acti‐
vation of the canonical Wntpathway [52].
Genes which code for the bone extracellular matrix proteins in osteoblast cells include alka‐
line phosphatase (AP), osteopontin (OP), osteocalcin (OC), and bone sialoprotein (BSP). This
data supports a potential regulatory mechanism that these matrix proteins play a critical
role in the development of biomineralization. To date, many of these markers have been
shown to be critical in the extracellular mineralization and bone formation that develops in
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normal osteoblast differentiation (Fig.5). Dr. Spelsberg and Dr. Rajamannan have extensive
experience in osteoblast cell biology and will contribute to the translational studies in the
aortic valve involving the differentiation and mineralization [53, 54].
A link between lipids and osteoporosis have been studied extensively [55-60]. These groups
have shown in in vitro and in vivo studies that lipids decrease bone formation and increase
vascular calcification. Hurska’s group from the University of Washington have studied this
important hypothesis in the LDLR-/- mice with renal disease [55]. This studied correlated the
important understanding of chronic kidney disease with decreased bone formation rates
and increase in vascular calcification. This study demonstrates that accelerated vascular cal‐
cification found in patients with end stage renal disease may be related to multifactorial
mechanisms including traditional atherosclerotic risk factors and elevated serum phosphate
levels. Giachelli has also studied extensively the hypothesis of a sodium phosphate abnor‐
mality in the vascular smooth muscle cell [61]. Her group has also shown that osteopontin
expression by vascular smooth muscle cells may have an inhibitory effect in the develop‐
ment of calcification [62] which further defines the complexity of the matrix synthesis phase
of bone formation. Demer’s laboratory has also studied extensively the correlation of lipids
with vascular calcification and osteoporosis via inhibition of Cbfa1 in osteoblast cells [60,
63]. This paradoxical finding between the calcifying vascular aorta and osteoporosis is an
important link in the hypercholesterolemia hypothesis. The development of cardiovascular
calcification is a multifactorial process which includes a number of mechanisms. Studies in
the different laboratories provide important evidence towards the development of therapies
depending on the patient population i.e. end stage renal disease versus treatment of the tra‐
ditional risk factors for vascular disease.
Our lab (43) and Towler’s laboratory (44) have shown that the Lrp5/Wnt/beta-catenin path‐
way plays an important role in the development of vascular and valvular calcification. Stud‐
ies have shown that different mutations in Lrp5, an LDL receptor related protein; develop a
high bone mass phenotype and an osteoporotic phenotype (45, 46). In the presence of the
palmitoylation of Wnt an active beta-catenin accumulates in the cytoplasm, presumably in a
signaling capacity, and eventually translocates to the nucleus via binding to nucleoporins
[64], where it can interacts with LEF-1/TCFs in an inactive transcription complex [65, 66],
The Wnt/Lrp5/frizzled complex turns on downstream components such as Dishevelled
(Dvl/Dsh) which leads to repression of the glycogen synthase kinase-3 (GSK3) [67]. Inhibi‐
tion of GSK3 allows beta-catenin to accumulate in the nucleus, interacting with members of
the LEF/TCF class of architectural HMG box of transcription factors including Cbfa1 in‐
volved in cell differentiation and osteoblast activation [68, 69, 70-72] and Sox 9, a HMG box
transcription factor, is required for chondrocyte cell fate determination and marks early
chondrocytic differentiation of mesenchymalprogenitors [73].
To determine a potential signaling pathway for the development of aortic valve disease
there are numerous pathways which may be implicated in this disease process [50, 74, 75].
Recent evidence suggests that the Wnt pathway regulates the expression of bone mineral
markers in cells responsive to the Wnt pathway. Furthermore the Wnt pathway has been
shown to be activated by lipids. Therefore we chose to assess this pathway in our model of
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experimental hypercholesterolemia to determine how lipids may be regulating Lrp5 in the
aortic valve. This background outlines the potential for lipids in the regulation of aortic
valve mineralization via the canonical Wnt pathway.
5. Echocardiography and Computerized Tomography (CT) evaluation of
the development of calcification and stenosis
Currently the non-invasive “gold standard” for the diagnosis of aortic valve stenosis is 2-
Dimensional doppler echocardiography. It is the test of choice to quantify the severity of
valve  stenosis  and  pressure  differential  across  the  aortic  valve.  There  are  a  increasing
number of studies which have demonstrated the utility of calculating the volume of calci‐
um and the rate of progression of the disease process in the aortic valve [76-80]. Confir‐
mation of hemodynamic valve stenosis by echo will provide the degree of valve stenosis
using ultrasound techniques4.  MicroCT will  assess  the  degree of  calcification within the
mineralizing tissues.
6. Development of future medical therapies for calcific aortic stenosis
The natural history studies of valvular aortic stenosis as defined by clinical and histopatho‐
logic parameters have provided landmark developments towards the understanding of this
disease. HMG CoA reductase inhibitors may provide an innovative therapeutic approach by
employing both lipid lowering and possibly non-lipid lowering effects to forestall critical
stenosis in the aortic valve. Our laboratory has shown that atorvastatin has a number of ef‐
fects in the aortic valve including: 1) inhibition of foam cell accumulation [6], 2) inhibition of
Cbfa1 activation [6], 3) eNOS enzymatic activation [11] and 4) attenuation of Lrp5 receptor
activation [81]. Statins have potent LDL lowering effects via inhibition of the rate-limiting
step in cholesterol synthesis. There are a number of experimental models which demon‐
strate the potential for treating the vasculature with statins to inhibit matrix formation [24,
25], cellular proliferation [6] and vascular aneurysm formation [82]. Although valve replace‐
ment is the current treatment of choice for severe critical aortic stenosis, future insights into
the mechanisms of calcification and its progression may indicate a role for lipid lowering
therapy in modifying the rate of progression of stenosis.
There are a growing number of retrospective studies demonstrating that statins may have
benefits in slowing the progression of aortic stenosis [83-85]. A recent clinical trial by Cowell
et al, demonstrated that high dose atorvastatin did not slow the progression of aortic steno‐
sis in patients [86]. However, the timing of the initiation of the statin therapy was at a later
stage of aortic valve disease. A clinical trial in Portugal called RAAVE- Rosuvastatin Affect‐
ing Aortic Valve Endothelium demonstrated prospectively that statins slow progression in
CAVD in an open label study. In the RAAVE study we found a change in aortic valve area
(AVA) in the control group was -0.10±0.09 cm2 per year versus -0.05 ±0.12 cm2 per yearin the
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Rosuvastatin group (p=0.041). In addition there was an increase in peak aortic valve velocity
was +0.24±0.30 m/sec/yr in the control group as compared to the increase in +0.04±0.38
m/sec/yr in the Rosuvastatin group (p=0.007), indicating that in this prospective hypothesis
driven study we found by echocardiography a slowing of progression in the aortic valve
disease. SALTIRE initiated atorvastatin in patients who had more advanced aortic stenosis
as defined by the mean aortic valve area 1.03 cm2 as compared to the average aortic valve
area in RAAVE of 1.23 cm2 as the baseline aortic valve area prior to treatment with Rosuvas‐
tatin [87]. The investigators of RAAVE hypothesize that the beneficial effect of the statin was
secondary to the early initiation of treatment. Furthermore, the SALTIRE investigators re‐
cently acknowledged the potential of medical therapies may be found if the treatment of this
disease is initiated earlier in the disease process [86]. The studies planned in this application
should lead to an important understanding of the molecular and cellular mechanisms of
aortic valve disease. Furthermore, the experimental approach will also correlate the devel‐
opment of valve calcium by MicroCT and hemodynamic progression by echocardiography
in this important disease process.
The bicuspid aortic valve (BAV) is the most common congenital cardiac anomaly, having a
prevalence of 0.9 to 1.37 % in the general population [3]. The natural history of the BAV is
progressive stenosis that typically occurs at a faster rate than tricuspid aortic valves requir‐
ing earlier surgical intervention in the BAV patients [2, 3]. With the decline of acute rheu‐
matic fever, calcific aortic stenosis has become the most common indication for surgical
valve replacement. Despite the high prevalence of aortic stenosis, few studies have investi‐
gated the mechanisms responsible for aortic valve disease. The cellular mechanism for the
development of this disease is not well known. Previously, we and others have demonstrat‐
ed that aortic valve calcification is associated with an osteoblast bone-like phenotype [14,
15]. This bone phenotype is regulated by the canonical Wnt pathway in experimental cardio‐
vascular calcification [5, 17]. We have alsoshown that the canonical Wnt/Lrp5 pathway is
upregulated in diseased human valves from patients with valvular heart disease [16]. These
studies implicate that inhibition of the canonical Wnt pathway provides a therapeutic ap‐
proach for the treatment of degenerative valvular heart diseases. A recent study [88], discov‐
ered that a loss of function mutation in Notch1 was associated with accelerated aortic valve
calcification and a number of congenital heart abnormalities. Normal Notch1 receptor func‐
tions to inhibit osteoblastogenesis [89, 90]. Evaluation of Notch1 gene and protein expres‐
sion in human bicuspid calcified valves compared to normal aortic valves removed at the
time of surgical valve replacement is shown in Figure 1, Panel A. Notch1 protein expression
was decreased in the BAV compared to controls by immunhistochemistry and Western Blot
expression Figure 1, Panel B1 and B2, and C. RNA expression by RTPCR indicates a spliced
Notch1 receptor in the diseased valves as compared to controls as shown in Figure 1, Panel
D. This Notch1 splicing may be the regulatory switch important for the activation of the
Wnt pathway and downstream calcification in these diseased valves [5, 17, 90].
Risk factors for the development of calcific aortic valve disease(CAVD) have been elucidated
in a number of epidemiologic databases [38]. The risk factors for CAVD are similar to those
of vascular atherosclerosis which include: elevated LDL, hypertension, male gender, smok‐
Oxidative Stress and Chronic Degenerative Diseases - A Role for Antioxidants270
ing and increased body mass index [38]. The elucidation of these risk factors have provided
the experimental basis for hypercholesterolemia as a method to induce aortic valve disease
[4-8. Furthermore, studies have shown that the eNOS-/- mouse is a novel mouse model which
develops anatomic bicuspid aortic valves (BAV) [91]. To understand if eNOS-/- mice with the
BAV phenotype, develops accelerated stenosis earlier than tricuspid aortic valves via the
Lrp5 pathway activation, eNOS-/- mice were given a cholesterol diet versus cholesterol and
atorvastatin. The Visual Sonics mouse echocardiography machine was used to screen for the
BAV phenotype. Echocardiography hemodynamics was also performed to determine the
timing of stenosis in bicuspid vs. tricuspid aortic valves eNOS-/- mice on different diets.
Figure 1. Histology of the aortic valves from human bicuspid calcified valves compared to normal aortic valves re‐
moved at the time of surgical valve replacement; Panel A. Bicuspid Aortic Valve Removed from patient at the time of
surgical valve replacement. Panel B1.Notch1 Immunohistochemistry of a Normal Aortic Valve. Panel B2.Notch1 Im‐
munohistochemistry of a Bicuspid Aortic Valve. Panel C. Notch1 protein expression was decreased in the BAV com‐
pared to controls by immunhistochemistry and Western Blot expression. Panel D. Notch1 RNA expression was
decrease in the BAV as compared to Control aortic Valve.
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Figure 2 demonstrates the characterization of the eNOS phenotype as defined by histology,
RTPCR and echocardiography. In Figure 2, Panel A is the histology for BAV, Figure 2, Panel
B is the semi-quantitative RTPCR from the BAV eNOS-/- mice, and echocardiographic data
for the bicuspid vs. tricuspid aortic valves Figure 2, Panel C. We measured Notch1, Wnt3a
and downstream markers of the canonical Wnt pathway by protein and RNA expression.
Notch1 protein was diminished and the RNA expression demonstrates a similar spliced var‐
iant with lipid treatments which was not present with the control and atorvastatin treat‐
ment. Cholesterol diets increased the members of the canonical Wnt pathway and
Atorvastatin diminished these markers significantly (p<0.05).
Figure 2. Characterization of the Bicuspid Aortic valve from the eNOS-/- bicuspid aortic valves. Panel A. Immunohisto‐
chemistry stain for Lrp5, Notch1, Proliferating Cell Nuclear Antigen, Osteopontin and Osteocalcin from the eNOS-/-
aortic valves on the control, Left column, control diet; middle column, cholesterol diet; right column, cholesterol diet
plus atorvastatin. In each panel, the aortic valve leaflet is in the center. (All frames 20X magnification) Panel B. RTPCR
for Wnt3a, Lrp5, Notch1, cyclin1, Osteopontin and Cbfa1 from the eNOS-/- aortic valves on the control, A1, Cholesterol
A2, and the Cholesterol + Atorvastatin diets A3. Panel C. Echocardiographic results of the tricuspid versus bicuspid
eNOS-/- null mice.
BAV is a complex model to study the mechanisms of calcification. The importance of cell-
cell communication within a stem cell niche is necessary for the development of valvular
heart disease. The two corollaries necessary for an adult stem cell niche is to first define the
physical architecture of the stem-cell niche and second is to define the gradient of prolifera‐
tion to differentiation within the stem-cell niche. The endothelial lining cell located along the
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aortic surface is responsible for the secretion of a growth factors [92]. These cells interact
with the subendothelial cells that are resident below the endothelial layer of cells. These
cells have been characterized as myofibroblast cells [75, 93, 94].
To test the hypothesis that BAV disease develops secondary to a stem cell niche process, the
physical cell-cell communication needed to be established [95]. In the aortic valve the com‐
munication for the stem cell niche would be between the aortic valve endothelial cell and
the adjacent myofibroblast cell located below the aortic lining endothelial cell. Conditioned
media was produced from untreated aortic valve endothelial cells for the microenvironment
that activates signaling in the myofibroblast cell. A mitogenic protein (Wnt3a) was isolated
from the conditioned media and then tested directly on the responding mesenchymal cell,
the cardiac valve myofibroblast [93, 96,95]. This transfer of isolated protein to the adjacent
cell was necessary to determine if the cell would proliferate directly in the presence of this
protein. This system is appealing because the responding mesenchymal cell is isolated from
the anatomic region adjacent and immediately below that of the endothelial cells producing
the growth factor activity along the fibrosa surface. Very little is known regarding the char‐
acterization of the endothelial cell conditioned media. These experiments test the corollary
that the physical architecture described above is necessary for disease development in the
aortic valve.
Figure 3 demonstrates the isolation and characterization of the Wnt3a from the conditioned
media microenvironment. Figure 3, Panel A, is light microscopy of aortic valve endothelial
cells isolated from the aortic surface of the aortic valve. The results of the mitogen assays for
fractions eluting from a DEAE- Sephadex column are shown in Figure 3, Panel B. It can be
seen that the mitogenic activity appeared as a single peak eluting at approximately 0.25 M
NaCl. The material eluting from DEAE- Sephadex was then applied to Sephadex G-100; the
results of mitogen assays on fractions eluting from such a gel filtration column are shown in
Figure 3, Panel C. It can be seen that under these native, non-denaturing conditions the bulk
of the mitogenic activity eluted as a peak corresponding to standard proteins of 30- 40,000
molecular weight. A SDS denaturing protein gel was run on each sample from the eluted
proteins and the bulk of activated protein correlated with the protein peak at 46kd as shown
in Figure 3, Panel D. The protein size and charge determination is similar to that previously
characterized as Wnt3a [97]. This material lost all activity when heated to 100oC for 5 mi‐
nutes; disulfide bond reduction with dithiothreitol also abolished all mitogenic activity; and
treatment with trypsin destroyed all activity, implicating a protein structure.
The second corollary for identifying a stem cell niche is to define the gradient responsible
for the proliferation to differentiation process. The main postulate for this corollary stems
from the risk factor hypothesis for the development of aortic valve disease. If traditional
atherosclerotic risk factors are necessary for the initiation of disease, then these risk factors
are responsible for the gradient necessary for the differentiation of myofibroblast cells to be‐
come an osteoblast calcifying phenotype [5, 17, 62, 75, 94, 95, 98, 99]. If traditional risk fac‐
tors are responsible for the development of valvular heart disease, then an oxidative stress
mechanism is important for the development of a gradient in this niche.
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Figure 3. Protein Isolation and Characterization of Aortic Valve Endothelial Cell Conditioned Media; Panel A. Light
Microscopy for Aortic Valve Endothelial Cells. Panel B. Cell Proliferation for fractions eluting from a DEAE- Sephadex
column. (p<0.001) Panel C. Fractions from DEAE- Sephadex to characterize weight with Sephadex G-100. (p<0.001)
Panel D. Southern Blot for Protein Expression of Fractions isolated form the DEAE-Sephadex column.
Nitric oxide is important in terms of the mechanism in adult disease processes and also in
the developmental abnormalities such as the bicuspid aortic valve phenotype in the eNOS
null mouse. To answer this question of the role of oxidative stress and nitric oxide in the
aortic valve, I performed in vitro experiments to determine eNOS enzymatic and protein reg‐
ulation in the presence of lipids and attenuation with Atorvastatin. We have previously
published that eNOS is regulated in the aortic valve in an experimental hypercholesterole‐
mia model of valvulardisease [11]. Figure 4, demonstrates the eNOS regulation in the endo‐
thelial cells in the presence of lipids with and without Atorvastatin. A number of standard
assays were performed to measure eNOS functional activity. Figure 4, Panel A1, tests for
eNOS enzymatic activity in the aortic valve endothelial cells (AEC) in the presence of LDL
with and without Atorvastatin. ENOS enzymatic activity was decreased in the presence of
lipids and Atorvastatin improved functional enzyme activity. Figure 4, Panel A2, shows re‐
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sults for tissue nitrites measured in the endothelial cells providing indirect evidence for the
enzyme activity. There was an increase is nitrites with lipid treatments and attenuation with
Atorvastatin. This increase in nitrite levels correlates with a decrease in the functional activi‐
ty of the eNOS enzyme in the aortic valve endothelium.
Figure 4. Evidence for eNOS regulation and Wnt3a Secretion from Aortic Valve Endothelial Cells. *p<0.001 for
control compared to cholesterol, **p<0.001 for cholesterol compared to cholesterol + Atorvastatin. Panel A1. eNOS
enzymatic activity in the aortic valve endothelial cells (AEC) in the presence of LDL with and without atorvastatin. Pan‐
el A2. Cell Nitrite activity in the aortic valve endothelial cells (AEC) in the presence of LDL with and without atorvasta‐
tin. Panel A3. Thymidine incorporation in LDL treated media, compared to AdeNOS treated myofibroblast cells, versus
control LacZ virus. Panel B1. Caveolin-1 and eNOS protein expression isolated from the lipid with and without atorvas‐
tatin treated cells as shown by Western Blot. Panel B2. Electron microscopy immunogold labeling for eNOS and Cav‐
eolin-1 localize in the aortic valve endothelial cells in caveolae. Panel C. Wnt3a Immunoprecipitate from Conditioned
Media treated with LDL with and without Atorvastatin.
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The proof of principle experiment to test the importance of eNOS enzymatic activity is an
overexpression experiment to determine if eNOS is able to inhibit cell proliferation, an early
cellular event in the development of aortic stenosis [13]. Experiments were performed to
overexpress eNOS to determine if eNOS overexpression in the aortic valve endothelial cells
would regulate cell proliferation. The in vitro myofibroblast cells were directly transduced
with an eNOS adenoviral gene construct. Thymidine incorporation was measured to test if
overexpressing eNOS can inhibit cellular proliferation. Figure 4, Panel A3, eNOS overex‐
pression inhibits the cell proliferation in the oxidized LDL treated cells induced as com‐
pared to the LacZ control treated cells.
A key regulator of eNOS function is caveolin-1 which is expressed in aortic valve endothe‐
lial cells [9. Caveolin-1 upregulation in the presence of lipids inactivates eNOS enzymatic
function and further promotes oxidative stress [100, 101]. Experiments were performed to
localize the expression of Caveolin1 and eNOS in the aortic valve endothelial cell caveolae.
A well defined mechanism to inactivate eNOS enzymatic activity is functional binding of
eNOS with caveolin1 in the presence of lipids [29, 95, 102]. Figure 4, Panel B1, demonstrates
that Caveolin-1 is upregulated in the lipid treated cells and decreases with atorvastatin treat‐
ment with no change in the eNOS protein expression as shown by Western Blot. Figure 4,
Panel B2, demonstrates the ultrastructural evidence by immunogold labeling for eNOS and
Caveolin-1 present in the aortic valve endothelial cells in caveolae, similar to previously re‐
ported data [9, 11]. This caveolin1 upregulation is indirect evidence in addition to the direct
data of a decrease in the enzyme activity, that caveolin-1 may play a similar role in AEC
found in the aortic valve similar to the vascular endothelium.
Experiments were performed to determine if Wnt3a secretion changes in the microenviron‐
ment of the aortic valve endothelial cells with and without lipids. Figure 4, Panel C, demon‐
strates that Wnt3a protein concentration in the conditioned media in the presence of LDL
with and without Atorvastatin. There is a significant increase in the protein with the lipids
and attenuation of this protein secretion with the Atorvastatin treatments. This experiment
tests the effects of lipids regulating the development of a “Wnt3a” gradient in the microen‐
vironment. If LDL increases Wnt3a secretion into the conditioned media or the microenvir‐
onment of the diseased aortic valve, this further contributes to the activation of the canonical
Wnt pathway in the subendothelial space of the aortic valve.
The final experiment to test the importance of a stem cell niche to activate the cellular osteo‐
blast gene program in the subendothelial layer cells was to test for the gene expression of
the Wnt/Lrp5 pathway in the myofibroblast cells. The stem cell niche is a unique model for
the development of an oxidative stress communication within the aortic valve endothelium.
As shown in Figure 5, oxidative stress contributes to the release of Wnt3a into the subendo‐
thelial space to activate Lrp5/Frizzeled receptor complex on the extracellular membrane of
the myofibroblast. This trimeric complex then induces glycogen synthase kinase to be phos‐
phorylated. This phosphorylation event causes ฀-catenin translocation to the nucleus. ฀-
catenin acts as a coactivator of osteoblast specific transcription factor Cbfa1 to induce
mesenchymalosteoblastogenesis in the aortic valve myofibroblast cell.
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Figure 5. Schematic Modeling for Calcification in the Aortic Valve Stem Cell Niche.
Adult tissues stem cells are a population of functionally undifferentiated cells, capable of (i)
homing (ii) proliferation, (iii) producing differentiated progeny, (iv) self-renewing, (v) re‐
generation, and (vi) reversibility in the use of these options. Within this definition, stem cells
are defined by virtue of their functional potential and not by a specific observable character‐
istic. This data is the first to implicate a cell-cell communication between the aortic valve en‐
dothelial cell and the myofibroblast cell to activate the canonical Wnt pathway. Lrp5 is
important in normal valve development [103], in this stem cell niche, reactivation of latent
Lrp5 expression [5, 16], regulates osteoblastogenesis in these mesenchymal cells. The two
corollary requirements necessary for an adult stem cell niche is to first define the physical
architecture of the stem-cell niche and second is to define the gradient of proliferation to dif‐
ferentiation within the stem-cell niche. The aortic valve endothelial cell communicates with
the myofibroblast cell to activate the myofibroblast to differentiate to form an osteoblast-like
phenotype [14]. This concept is similar to the endothelial/mesenchymal transition critical in
normal valve development [104]. This data fulfills these main corollaries of the plausibility
of a stem cell niche responsible for the development of valvular heart disease. Within a stem
cell niche there is a delicate balance between proliferation and differentiation. Cells near the
stem-cell zone are more proliferative, and Wnt likely plays a role in directing cell differentia‐
tion. Stem cell behavior is determined by the number of its stem cell neighbors, which in the
valve is the endothelial cell. This assumption is aimed at simply describing the fact that cy‐
tokines, secreted by cells into the micro-environment are capable of activating quiescent
stem cells into differentiation [105].
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The important inhibitor in this model is Notch1. Notch1 plays a roll in cellular differentia‐
tion decisions. In the osteoblast cell, it serves as an inhibitor of osteoblast differentiation [89,
90]. In the aortic valve, it serves to turn off bone formation via the cell-cell crosstalk between
the endothelial and the myofibroblast cells. Normal Notch1 receptor functions to maintain
normal valve cellular composition and homeostasis. In the presence of lipids, Notch1 is
spliced and therefore activates osteoblastogenesis. In turn, the Wnt3a is secreted and binds
to Lrp5 and Frizzled on the extracellular membrane to regulate the osteoblast gene program.
This developmental disease process follows a parallel signaling pathway that has been ob‐
served in the normal embryonic valve development that has been well delineated by previ‐
ous investigators [104]. A similar cell-cell communication is necessary for the development
of valve disease.
This study provides the correlates described in the mathematical modeling by Agur [106].
This mathematical model has demonstrated the principal that the universal properties of the
stem cells can be described in a simple discrete model as derived from hemopoietic stem cell
behavior [106]. The transition of hemopoietic stem cells from quiescence into differentiation,
is governed by their cell-cycling status, by stimulatory hormones secreted by neighboring
cells into the micro-environment and by the level of amplification of stem-cell population
[105, 107]. The model of Agur, defines the corollaries necessary to identify a stem cell niche,
first the physical architecture of the stem cell niche and second the gradient necessary to reg‐
ulate the niche. In the BAV the gradient is defined by the niche’s microenvironment. The ini‐
tiation of event of oxidative stress inhibits normal endothelial nitric oxide synthase function,
activates notch1 splicing which in turn induces Wnt3a secretion to activate bone formation
within the valve [5, 17], [99].
The model proposed in the study as described in Figure 5, provides the cellular architecture
for the development of this disease process. This model does not take into account other cy‐
tokine/growth factor mediated mechanisms that have been shown to also be important in
this disease process [108]. However, understanding CAVD from a development disease per‐
spective will provide a foundation for understanding this and other development disease
processes. Clinical trials in the field of CAVD are demonstrating variable results [86, 87].
The possible differences in the published trials are secondary to the timing of therapy and
the biological targeting of the lipid levels in these patients. Future medical therapies target‐
ing stem cell niche mediated diseases provides a novel model system to test and to translate
clinically for patients in the future.
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